Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 54903 (Ciclesonide) in Asthma Inadequately Controlled on ICS
NCT01396278Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Primary completion
- Dec 2011
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olodaterol in asthma (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Mean Change in Trough Forced Expiratory Volume in One Second at 8 weeks. Started Jul 2011; status: terminated.
02
Drugs
olodaterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01396278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396278.